Moderna said it is in talks with the FDA over Phase 4 COVID-19 vaccine data that could restore broader use after regulators narrowed the label last year. The company framed the work as supplying post-marketing evidence tied to real-world performance and ongoing immunization policy. The disclosure arrives amid Moderna’s financial recovery efforts, including cost reductions and growing investor focus on oncology programs. Still, regulatory access to COVID vaccines remains a near-term revenue and credibility lever. From a biotech-industry perspective, the situation highlights the regulatory pathway for mRNA products transitioning from initial emergency authorization to post-marketing label definitions. Any resulting label expansion or limitation would feed directly into partner and procurement decisions for vaccine supply chains.